thalidomide has been researched along with aclarubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gui, R; Li, M; Li, Z; Song, Y; Wei, X; Zhang, Y; Zhao, H; Zhou, J; Zu, Y | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
1 trial(s) available for thalidomide and aclarubicin
| Article | Year |
|---|---|
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Remission Induction; Thalidomide | 2018 |
1 other study(ies) available for thalidomide and aclarubicin
| Article | Year |
|---|---|
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Thalidomide | 2016 |